339 related articles for article (PubMed ID: 36750049)
1. Belimumab for the treatment of pediatric patients with lupus nephritis.
Stohl W; Kwok A
Expert Opin Biol Ther; 2023 Mar; 23(3):243-251. PubMed ID: 36750049
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the treatment of systemic lupus erythematosus with belimumab in children.
Deng WP
Zhongguo Dang Dai Er Ke Za Zhi; 2021 Oct; 23(10):1069-1074. PubMed ID: 34719425
[TBL] [Abstract][Full Text] [Related]
3. 10 Years of belimumab experience: What have we learnt?
Levy RA; Gonzalez-Rivera T; Khamashta M; Fox NL; Jones-Leone A; Rubin B; Burriss SW; Gairy K; Maurik AV; Roth DA
Lupus; 2021 Oct; 30(11):1705-1721. PubMed ID: 34238087
[TBL] [Abstract][Full Text] [Related]
4. Belimumab for systemic lupus erythematosus - Focus on lupus nephritis.
Plüß M; Piantoni S; Tampe B; Kim AHJ; Korsten P
Hum Vaccin Immunother; 2022 Nov; 18(5):2072143. PubMed ID: 35588699
[TBL] [Abstract][Full Text] [Related]
5. New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab.
Staveri C; Karokis D; Liossis SC
Semin Arthritis Rheum; 2017 Jun; 46(6):788-790. PubMed ID: 27793432
[TBL] [Abstract][Full Text] [Related]
6. Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab.
Guzman M; Hui-Yuen JS
Drug Des Devel Ther; 2020; 14():2503-2513. PubMed ID: 32612353
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology considerations for the approval of belimumab for the treatment of adult patients with active lupus nephritis: A regulatory perspective.
Liu T; Neuner R; Thompson A; Pottackal G; Petullo D; Liu J; Nikolov N; Sahajwalla C; Doddapaneni S; Chen J
Lupus; 2022 Apr; 31(4):424-432. PubMed ID: 35238725
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
Jordan NP; D'Cruz DP
Expert Opin Drug Metab Toxicol; 2015; 11(10):1635-45. PubMed ID: 26327145
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial.
van Schaik M; Arends EJ; Soonawala D; van Ommen E; de Leeuw K; Limper M; van Paassen P; Huizinga TWJ; Toes REM; van Kooten C; Rotmans JI; Rabelink TJ; Teng YKO
Trials; 2022 Nov; 23(1):939. PubMed ID: 36371234
[TBL] [Abstract][Full Text] [Related]
10. Belimumab for systemic lupus erythematosus.
Singh JA; Shah NP; Mudano AS
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD010668. PubMed ID: 33631841
[TBL] [Abstract][Full Text] [Related]
11. Efectiveness of belimumab in the treatment of lupus nephritis: analysis of 8 cases.
de la Rubia Navarro M; Ivorra Cortés JR; Grau García E; Román Ivorra JA
Med Clin (Barc); 2022 Oct; 159(7):344-346. PubMed ID: 35811138
[TBL] [Abstract][Full Text] [Related]
12. Belimumab for the treatment of systemic lupus erythematosus.
Jordan N; D'Cruz DP
Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
[TBL] [Abstract][Full Text] [Related]
13. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.
Dooley MA; Houssiau F; Aranow C; D'Cruz DP; Askanase A; Roth DA; Zhong ZJ; Cooper S; Freimuth WW; Ginzler EM;
Lupus; 2013 Jan; 22(1):63-72. PubMed ID: 23263865
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Telitacicept in a systemic lupus erythematosus patient with suboptimal response to Belimumab: A case report.
Huang L; Qian G; Zhang H; Li Q; Chen L; Tang X; Zhao H
Lupus; 2024 Feb; 33(2):172-175. PubMed ID: 38081170
[TBL] [Abstract][Full Text] [Related]
15. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population.
Yu X; Chen N; Xue J; Mok CC; Bae SC; Peng X; Chen W; Ren H; Li X; Noppakun K; Gilbride JA; Green Y; Ji B; Liu C; Madan A; Okily M; Tang CH; Roth DA
Am J Kidney Dis; 2023 Mar; 81(3):294-306.e1. PubMed ID: 36058429
[TBL] [Abstract][Full Text] [Related]
17. Belimumab: review of use in systemic lupus erythematosus.
Boyce EG; Fusco BE
Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
[TBL] [Abstract][Full Text] [Related]
18. The safety of belimumab for the treatment of systemic lupus erythematosus.
Wise LM; Stohl W
Expert Opin Drug Saf; 2019 Dec; 18(12):1133-1144. PubMed ID: 31657965
[No Abstract] [Full Text] [Related]
19. Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report.
Fontana F; Alfano G; Leonelli M; Cerami C; Ligabue G; Spinella A; Citriniti G; Manzini CU; Ferri C; Cappelli G
BMC Nephrol; 2018 Oct; 19(1):276. PubMed ID: 30342482
[TBL] [Abstract][Full Text] [Related]
20. Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials.
Steiger S; Ehreiser L; Anders J; Anders HJ
Front Immunol; 2022; 13():999704. PubMed ID: 36211360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
